UNSPSC 51183111: Meglitinide

This classification denotes an anti-diabetic agent with the molecular formula C17H16ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 8V6OK1I088, chemically known as benzoic acid, 4-(2-((5-chloro-2-methoxybenzoyl)amino)ethyl)- but more generally known as meglitinide, which bears US NIH Compound Identifier 41214. European Medicines Agency schedules Meglitinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08713MIG.

UNSPSC 51183111 Meglitinide, a Commodity code, covers prescription pharmaceutical products supplied to state and local government health systems, correctional facilities, and other public health operations. State and local procurement under this code focuses on establishing framework contracts with pharmaceutical manufacturers for multi-source generics and branded products, with pricing, product availability, and supply-chain compliance as the primary evaluation factors. Issuing bodies include state departments of administration and health, cooperative purchasing alliances spanning multiple states, and subordinate facilities within those networks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary vehicle for consolidated state and local pharmaceutical procurement across participating jurisdictions.

MMCAP's January 2026 RFP for Generic Multi-Source Pharmaceuticals and OTC Products (S1070000015802), due March 26, 2026, exemplifies current activity under the code. The solicitation seeks manufacturers willing to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) across Minnesota and Oregon, with award effective July 1, 2026 and contract terms running two years for new vendors through June 30, 2028. Evaluation emphasizes price competitiveness (75 percent weight), compliance with administrative data formats and EDI capability (5 percent each), fixed pricing structure (10 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must demonstrate cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of the three wholesalers, and carry $5 million commercial general liability coverage. No specific dollar ceiling or set-aside restrictions are disclosed; however, performance penalties of $200 to $1,500 per violation apply for reporting delays, missed onboarding timelines, or class-of-trade denials.